SHARE TEXT
 
David R. Andes, MD close
Tvg6uXVvHQc
David R. Andes, MD
 

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

David R. Andes, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Andes’ clinical interests include general infectious diseases, transplant infectious diseases, mycology, antimicrobial pharmacokinetics and pharmacodynamics. 

Specialties

Infectious Diseases

Travel Medicine

Clinics

University Hospital
(608) 263-0946 | (800) 323-8942 | Map
University Hospital
(608) 890-6167 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Infectious Diseases
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School University of Missouri School of Medicine, Columbia, MO

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

The overriding themes of our research programs are to advance our understanding of antibacterial and antifungal activity and drug resistance, and to identify new antimicrobial drug treatment strategies and drug targets.


PubMed Articles
Lepak AJ Zhao M Marchillo K VanHecker J Andes DR <i>In Vivo</i> Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. Antimicrob Agents Chemother . 2019 Jul;63(7)
[PubMed ID: 31036691]
Rodríguez López AL Lee MR Wang NB Dunn KK Sanchez H Raman N Andes DR Lynn DM Palecek SP Small-molecule morphogenesis modulators enhance the ability of 14-helical β-peptides to prevent <i>Candida albicans</i> biofilm formation. Antimicrob Agents Chemother . 2019 Jun 17;
[PubMed ID: 31209011]
Okusanya OO Forrest A Bhavnani SM Fernandes P Ambrose PG Andes DR Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin Against <i>Streptococcus pneumoniae</i> Using Data from a Neutropenic Murine-Lung Infection Model. Antimicrob Agents Chemother . 2019 Jun 10;
[PubMed ID: 31182534]
Misch EA Andes DR Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. Infect Dis Clin North Am . 2019 Jun;33(2):399-445
[PubMed ID: 31005135]
Andes D Has the Optimal Therapy for Invasive Candidiasis Now Been Defined? Clin Infect Dis . 2019 May 30;68(12):1990-1992
[PubMed ID: 30289475]
Wicha WW Craig WA Andes D In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model. J Antimicrob Chemother . 2019 Apr 1;74(Supplement_3):iii5-iii10
[PubMed ID: 30949706]
Zhao M Lepak AJ Marchillo K Vanhecker J Sanchez H Ambrose PG Andes DR APX001 Pharmacokinetic/Pharmacodynamic Target Determination against <i>Aspergillus fumigatus</i> in an <i>In Vivo</i> Model of Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother . 2019 Apr;63(4)
[PubMed ID: 30670426]
Kaindl T Andes D Engelhardt M Saulay M Larger P Groll AH Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. J Antimicrob Chemother . 2019 Mar 1;74(3):761-767
[PubMed ID: 30476108]
Lepak AJ Zhao M Liu Q Wang P Wang Y Bader JC Ambrose PG Andes DR Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother . 2019 Mar;63(3)
[PubMed ID: 30559140]
Robinett NG Culbertson EM Peterson RL Sanchez H Andes DR Nett JE Culotta VC Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis. J Biol Chem . 2019 Feb 22;294(8):2700-2713
[PubMed ID: 30593499]
Sundermann AJ Clancy CJ Pasculle AW Liu G Cumbie RB Driscoll E Ayres A Donahue L Pergam SA Abbo L Andes DR Chandrasekar P Galdys AL Hanson KE Marr KA Mayer J Mehta S Morris MI Perfect J Revankar SG Smith B Swaminathan S Thompson GR Varghese M Vazquez J Whimbey E Wingard JR Nguyen MH How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. Clin Infect Dis . 2019 Feb 15;68(5):850-853
[PubMed ID: 30299481]
Chevrette MG Carlson CM Ortega HE Thomas C Ananiev GE Barns KJ Book AJ Cagnazzo J Carlos C Flanigan W Grubbs KJ Horn HA Hoffmann FM Klassen JL Knack JJ Lewin GR McDonald BR Muller L Melo WGP Pinto-Tomás AA Schmitz A Wendt-Pienkowski E Wildman S Zhao M Zhang F Bugni TS Andes DR Pupo MT Currie CR The antimicrobial potential of Streptomyces from insect microbiomes. Nat Commun . 2019 Jan 31;10(1):516
[PubMed ID: 30705269]
Andes DR Ghannoum MA Mukherjee PK Kovanda LL Lu Q Jones ME Santerre Henriksen A Lademacher C Hope WW Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Antimicrob Agents Chemother . 2019 Jan;63(1)
[PubMed ID: 30373791]
Koo H Andes DR Krysan DJ Candida-streptococcal interactions in biofilm-associated oral diseases. PLoS Pathog . 2018 Dec;14(12):e1007342
[PubMed ID: 30543717]
Bader JC Lakota EA Andes DR Rubino CM Ambrose PG Bhavnani SM Time for Precision: A World Without Susceptibility Breakpoints. Open Forum Infect Dis . 2018 Dec;5(12):ofy282
[PubMed ID: 30581880]
Lepak AJ Zhao M Andes DR Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model. Antimicrob Agents Chemother . 2018 Nov;62(11)
[PubMed ID: 30181375]
Zarnowski R Sanchez H Covelli AS Dominguez E Jaromin A Bernhardt J Mitchell KF Heiss C Azadi P Mitchell A Andes DR Candida albicans biofilm-induced vesicles confer drug resistance through matrix biogenesis. PLoS Biol . 2018 Oct;16(10):e2006872
[PubMed ID: 30296253]
Zhao M Lepak AJ Marchillo K VanHecker J Andes DR <i>In Vivo</i> Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model. Antimicrob Agents Chemother . 2018 Sep;62(9)
[PubMed ID: 29987156]
Owens RC Jr Bulik CC Andes DR Pharmacokinetics-pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder. Diagn Microbiol Infect Dis . 2018 Aug;91(4):371-382
[PubMed ID: 29776710]
Andes D Kovanda L Desai A Kitt T Zhao M Walsh TJ Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. Antimicrob Agents Chemother . 2018 Jul;62(7)
[PubMed ID: 29735569]